MATERIALISE - BUY | USD38 VS. USD39 (+77%) Recovery is clearly engaged
MATERIALISE - BUY | USD38 VS. USD39 (+77%)Recovery is clearly engaged
We reiterate our Buy rating and adjust our TP to USD38 from USD39
Medical and Manufacturing divisions performed above expectations
FY21 adj. EBITDA guidance is just a shade below our forecasts
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.